GW Pharmaceuticals Plc, which has developed a cannabinoid-based product for treating spasticity due to multiple sclerosis, has priced an initial public offering of its shares at $8.90 per American Depositary Share. The shares will trade on NASDAQ. ---Subscribe to MedNous to access this article--- Company News
